Alkermes PLC is a leading biotechnology company that has carved out a significant niche in the medical community by developing innovative treatments for central nervous system disorders.

Alkermes PLC reported mixed Q1 2025 financial results, with revenue exceeding expectations but earnings decreasing, as the company advances its Orexin 2 program and addresses complex health issues like Alcohol Use Disorder.